GlobeNewswire PharmaOriginal article
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
ConferenceSION-719SION-451SION-2222Positive
AI Analysis
Summary
Sionna Therapeutics will present post hoc analyses of SION-719 at the 2026 North American Cystic Fibrosis Conference, with data supporting advancement of the SION-451 + SION-2222 combination into the AscenSION CF Phase 2a proof-of-concept trial.
Clinical Trial Data
Phase
2a
Outcome Details
Post hoc analyses of SION-719 support advancement of combination SION-451 + SION-2222 into Phase 2a trial
Importance:5/10
Sentiment:
0.60
cystic_fibrosisclinical_trialphase_2conference_presentationcombination_therapy
Related Companies
Read the original article
Published by GlobeNewswire Pharma on October 8, 2026 8:30 PM